Seemal R. Desai, MD

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.

Advice for Dermatologists in Treating Psoriasis in Patients With Skin of Color

This is a video synopsis/summary of a panel discussion involving Linda Stein Gold, MD; Mona Shahriari, MD, FAAD; and Seemal Desai, MD.

The discussion focuses on the implications of research findings for patients with skin of color in psoriasis treatment. The speakers emphasize the importance of utilizing data-driven approaches to guide treatment decisions and advocate for increased diversity in clinical trial participation to ensure representative study populations.

They discuss the significance of cultural sensitivity in patient interactions and highlight the need for continued investment in research and development to generate data that can inform clinical practice effectively. The transcript concludes with a call to action for dermatologists to play a critical role in improving outcomes for all patients with psoriasis, underscoring the value of sharing knowledge and fostering collaboration within the medical community.

Overall, the conversation emphasizes the importance of evidence-based approaches, cultural competence, and ongoing research efforts in addressing the needs of diverse patient populations with psoriasis.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Videos

Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share how they utilize biologics data from skin of color cohorts in their practice.

Data with Biologics in Patients With Skin of Color

The conversation revolves around the significance of post-hoc analyses in biologic studies for patients with skin of color, emphasizing their importance in guiding treatment decisions. While these analyses may not replicate the rigor of randomized controlled trials, they provide valuable insights into treatment efficacy and safety for diverse patient populations.

The discussion highlights various studies, including systematic reviews and specific biologic trials, which have examined treatment outcomes in patients with skin of color. It is noted that despite the need for more dedicated studies with larger sample sizes, post-hoc analyses reveal promising results, indicating comparable treatment responses and safety profiles across different ethnicities.

The speakers stress the relevance of this data in clinical practice, particularly in addressing patient concerns and building trust in the healthcare system. By utilizing the findings from these analyses, clinicians can tailor treatment recommendations based on individual patient needs and preferences.

Furthermore, the conversation touches upon the role of conferences and meetings in disseminating research findings, underscoring the importance of raising awareness and promoting inclusivity in clinical trial participation. Despite the challenges posed by limited representation in large clinical trials, the speakers express optimism about the potential of dedicated studies to provide comprehensive insights into treatment outcomes for patients with skin of color.

Data With Biologics in Patients With Skin of Color

share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.

Early Use of Systemic Treatments in Patients With Skin of Color

The discussion delves into the challenges of initiating systemic therapy for psoriasis patients and how to effectively communicate its necessity. It emphasizes the importance of early intervention to prevent future complications and improve patient outcomes, regardless of ethnicity or skin type.

An expert dermatologist emphasizes the need to view all psoriasis patients equally and highlights the significance of data from studies like VISIBLE in supporting treatment decisions. He stresses the importance of addressing patient concerns such as safety, cost, and distrust in the medical system, while framing the conversation around collaboration between patient and physician.

Furthermore, the discussion touches upon the potential benefits of early treatment in minimizing post-inflammatory hyperpigmentation (PIH) and the ongoing research to elucidate the pathophysiology of PIH across different diseases. While the exact mechanisms are not yet fully understood, ongoing research aims to provide more insights into the nuances of PIH in various dermatological conditions.

Overall, the conversation underscores the importance of proactive treatment approaches and ongoing research efforts to improve outcomes for psoriasis patients, irrespective of their background or skin type.

Drs Stein Gold and Desai share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.

Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.

Results of VISIBLE Trial in Patients With Skin of Color

The conversation revolves around the significant findings of the Visible study, which focused on understanding psoriasis treatment outcomes in patients with skin of color. The trial demonstrated the efficacy of guselkumab in both traditional plaque psoriasis patients (cohort A) and those with scalp involvement (cohort B). Particularly noteworthy were the results from cohort B, where a high percentage of patients achieved complete clearance, indicating significant improvement for this patient population.

The study generated a vast database of over 20,000 images, which will serve as a valuable resource for medical education and improving disease management. The speakers emphasize the importance of such resources in educating dermatologists worldwide, especially in regions with diverse skin types.

Furthermore, the study's results suggest a shift towards earlier consideration of systemic therapy for psoriasis patients, especially those with skin of color. Early intervention can potentially prevent post-inflammatory pigment alterations and improve patients' quality of life.

The transcript highlights real-life impact stories, such as a patient who experienced transformative results from the drug, leading to improved quality of life and increased confidence. Additionally, the study revealed that nearly half of the patients reported no impact of psoriasis on their daily lives, underscoring the remarkable success of the treatment.

Overall, the VISIBLE study represents a significant advancement in understanding and managing psoriasis in diverse patient populations, emphasizing the need for early intervention and tailored treatment approaches.

Seemal R. Desai, MD

Articles